GBT - Global Blood Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Global Blood Therapeutics, Inc.

171 Oyster Point Boulevard
Suite 300
South San Francisco, CA 94080
United States

Full Time Employees147

Key Executives

NameTitlePayExercisedYear Born
Dr. Ted W. LovePres, CEO & Director711.88kN/A1959
Dr. Charles J. HomcyFounder, Advisor & Director41.29kN/A1948
Mr. Jeffrey S. FarrowChief Financial Officer416.22kN/A1962
Mr. Peter RadovichSr. VP of OperationsN/AN/A1978
Dr. Hing ShamSr. VP of ResearchN/AN/A1952
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.

Corporate Governance

Global Blood Therapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2018 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.